Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03915067 · ClinicalTrials.gov registry record · Phase 2
BOTOX® for the Treatment of Platysma Prominence
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 171
- Enrollment target
NCT03915067: Completed Phase 2 study, sponsored by Allergan.
NCT03915067 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 171 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (29% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03915067, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 171 participants
- Enrollment target
Study Summary
To assess the efficacy and safety of BOTOX® in adults with moderate to severe platysma prominence.
Primary Outcome
The investigator evaluated the participant's platysma prominence severity using a 5-grade scale C-APPS at maximum contraction where 1= minimal, and 5= extreme. Higher values indicate worsening condition. Data is reported for participants who achieved at least a 1-grade improvement rated on the C-APPS. Percentages are rounded off to whole number at the nearest decimal. Cochran-Mantel-Haenszel (CMH) chi-squared test was used for analysis.
Interventions
- DRUG Placebo
- DRUG BOTOX® purified neurotoxin complex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2019-04-23 |
| Est. Completion | 2020-04-16 |
| Phase | Phase 2 |
What the finished NCT03915067 record still lists
NCT03915067 is an interventional study that assigns participants to a tested intervention. The registered 171 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (29% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03915067 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03915067 about?
NCT03915067 is a clinical study titled "BOTOX® for the Treatment of Platysma Prominence". To assess the efficacy and safety of BOTOX® in adults with moderate to severe platysma prominence.
What is the current status of trial NCT03915067?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 171 participants. The study started on 2019-04-23. Estimated completion is 2020-04-16.
What interventions are being tested in trial NCT03915067?
The interventions under investigation include: Placebo (DRUG), BOTOX® purified neurotoxin complex (DRUG).
Who is sponsoring clinical trial NCT03915067?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03915067's enrollment target sits among peer trials
171 398th of 2000 higher than 1,602 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02641145 · 171 participants · NA
Molecular Imaging of Primary Amyloid Cardiomyopathy
- NCT05541029 · 171 participants · NA
Music Listening: A Mechanistic Trial
- NCT05561127 · 171 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel
- NCT05592938 · 171 participants · NA
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI